Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

IARTยทNASDAQ

$16.10

+2.7%
HealthcareMedical - Devices

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

At a Glance

Live Snapshot
Market Cap$1.25B
EPS-6.7300
P/E Ratio-2.39
Earnings Date07/30/2026
3Y+5.0%
5Y+19.0%
10Y+65.0%
3Y-386.0%
5Y-486.0%
10Y-793.0%
3Y-81.0%
5Y-75.0%
10Y-57.0%
Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation Profit Bridge

IART ยท NASDAQ
Revenue1.64B
Cost of Goods Sold (790.01M)
Gross Profit845.23M
Operating Expenses (776.92M)
Operating Income68.32M
Interest Expense (86.25M)
Other Income/Expense-631.82M
Pretax Income-563.50M
Income Tax (-47.03M)
Net Income-516.47M
Net Income
-516.47M

Profitability Analysis

Gross Margin

51.7%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

4.2%

Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.

Net Profit Margin

-31.6%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

Integra LifeSciences Holdings Corporation Income Statement

IART โ€ข NASDAQ

Integra LifeSciences Holdings Corporation Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
1.6B
1.6B
1.5B
1.6B
1.5B
1.4B
1.5B
1.5B
1.2B
992.1M
882.7M
928.3M
836.2M
830.9M
780.1M
732.1M
682.5M
654.6M
550.5M
419.3M
GROSS PROFIT
(790M)
(728.5M)
(656.8M)
(587.4M)
(597.8M)
(520.8M)
(564.7M)
(571.5M)
(435.5M)
(349.1M)
(326.5M)
(352.8M)
(334.1M)
(314.4M)
(299.2M)
(268.2M)
(244.9M)
(252.8M)
(214.7M)
(168.3M)
845.2M
882.1M
884.7M
970.3M
944.6M
851M
952.9M
900.9M
752.7M
643M
556.2M
575.5M
502.1M
516.4M
480.9M
463.9M
437.6M
401.8M
335.8M
251M
OPERATING INCOME
(776.9M)
(853.7M)
(773.2M)
(731.4M)
(747.4M)
(699.7M)
(794.2M)
(789.9M)
(707.9M)
(527.6M)
(476.6M)
(510M)
(459M)
(442.7M)
(426M)
(365.2M)
(339.7M)
(354.4M)
(268.5M)
(192.2M)
(699.7M)
(717M)
(656.6M)
(616.3M)
(637.4M)
(594.5M)
(687.6M)
(690.7M)
(624.1M)
(455.6M)
(415.8M)
(446M)
(394.3M)
(373.1M)
(358.1M)
(305.1M)
(281.1M)
(281M)
(225.2M)
(157.7M)
(99M)
(115.4M)
(104.2M)
(101.2M)
(93.1M)
(77.4M)
(79.6M)
(78M)
(63.5M)
(58.2M)
(50.9M)
(51.6M)
(52.1M)
(51M)
(51.5M)
(48.1M)
(44.3M)
(60.5M)
(30.7M)
(25.7M)
68.3M
28.4M
111.5M
238.9M
197.2M
151.4M
179M
111M
44.8M
115.3M
79.6M
65.5M
-3.6M
73.8M
54.9M
98.7M
97.8M
47.4M
67.3M
58.7M
PRE-TAX INCOME
(86.3M)
(70.6M)
(51.4M)
(49.6M)
(50.4M)
(71.6M)
(54M)
(64.7M)
(35M)
(25.8M)
(23.5M)
(22M)
(19.7M)
(22.2M)
(27.6M)
(18.4M)
(23.2M)
(30.1M)
(0.0)
(0.0)
-67.8M
-50.6M
-34.2M
-37.7M
-43.7M
-62.3M
-43.2M
-61.9M
-34.8M
-25.8M
-23.5M
-21.8M
-14.8M
-21M
-27.2M
-18.1M
-22.6M
-28M
0.0
0.0
-21.8M
(21.3M)
(12.4M)
(13.9M)
(16.9M)
(27.8M)
(27M)
(8.3M)
(1.3M)
(845K)
(4.6M)
-763K
-1.8M
-721K
(16.4M)
(12M)
(14.4M)
(12.9M)
(12.7M)
(8.8M)
-631.8M
-46.6M
-30.5M
-25M
17.4M
-57.9M
-33.7M
-53.6M
-33.4M
-24.9M
-18.9M
-24.9M
-21.1M
-21.8M
-26.4M
-16.6M
-24.7M
-16.4M
-7.2M
-10.4M
-563.5M
-18.2M
81.1M
213.9M
214.7M
93.5M
60.1M
57.4M
11.4M
90.4M
60.7M
43M
-24.8M
52M
28.5M
82.1M
73.2M
31M
60.1M
48.3M
NET INCOME
-47M
-11.3M
(13.3M)
(33.3M)
(45.6M)
-40.4M
(9.9M)
-3.4M
-53.4M
(15.8M)
(53.8M)
(9M)
-7.8M
(10.8M)
(505K)
(16.4M)
(22.2M)
-3.9M
(26.6M)
(18.9M)
-516.5M
-6.9M
67.7M
180.6M
169.1M
133.9M
50.2M
60.8M
64.7M
74.6M
-3.5M
34M
-17M
41.2M
28M
65.7M
51M
34.9M
33.5M
29.4M

SEC Filings

IART - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 08, 2026
May 07, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
May 05, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 05, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
April 30, 2026
2026
8-K

8-K 2026

N/A

April 15, 2026
April 10, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 06, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2025

N/A

December 12, 2025
December 11, 2025
2025
10-Q

10-Q 2025 Q3

Q3

October 30, 2025
September 30, 2025
2025
Showing 1 to 10 of 575 filings